Commission Regulation (EC) No 1729/2006 of 23 November 2006 amending Annexes I and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards firocoxib and triclabendazole   (Text with EEA relevance)
Date: 2006-11-23
Institutions: European Commission
Subjects: animal product, food inspection, foodstuff, veterinary drug, veterinary legislation

L 325/6

EN

Official Journal of the European Union

24.11.2006

COMMISSION REGULATION (EC) No 1729/2006

of 23 November 2006

amending Annexes I and III to Council Regulation (EEC) No 2377/90 laying down a Community
procedure for the establishment of maximum residue limits of veterinary medicinal products in
foodstuffs of animal origin, as regards firocoxib and triclabendazole

(Text with EEA relevance)

THE COMMISSION OF THE EUROPEAN COMMUNITIES,

Having regard to the Treaty
Community,

establishing the European

Having regard to Council Regulation (EEC) No 2377/90 of 26
June 1990 laying down a Community procedure for the estab-
lishment of maximum residue limits of veterinary medicinal
products in foodstuffs of animal origin (1), and in particular
Article 2 and the third paragraph of Article 4 thereof,

the European Medicines
Having regard to the opinions of
Agency formulated by the Committee for Medicinal Products
for Veterinary Use,

Whereas:

include triclabendazole in that Annex for all ruminants
for muscle,
liver and kidney, excluding animals
producing milk for human consumption amending the
maximum residue limits values.

fat,

(4)

Regulation (EEC) No 2377/90 should therefore be
amended accordingly.

(5)

(6)

An adequate period should be allowed before the appli-
cability of this Regulation in order to enable Member
States to make any necessary adjustment in the light of
this Regulation to the authorisations
to place the
veterinary medicinal products concerned on the market
which have been granted in accordance with Directive
2001/82/EC of
the
Council of 6 November 2001 on the Community code
relating to veterinary medicinal products (2).

the European Parliament and of

The measures provided for in this Regulation are in
Standing
the
the
accordance with
Committee on Veterinary Medicinal Products,

opinion

of

All pharmacologically active substances used in the
Community in veterinary medicinal products intended
should be evaluated in
for
accordance with Regulation (EEC) No 2377/90.

food-producing animals

HAS ADOPTED THIS REGULATION:

Following examination of an application for the estab-
lishment of maximum residue limits for firocoxib in
Equidae and in order to allow for the completion of
minor scientific validation of studies,
is considered
appropriate to include firocoxib in Annex III to Regu-
lation (EEC) No 2377/90 for Equidae species.

it

Article 1

Annexes I and III to Regulation (EEC) No 2377/90 are amended
in accordance with the Annex to this Regulation.

The substance triclabendazole is included in Annex I to
Regulation (EEC) No 2377/90 for bovine and ovine for
muscle, kidney and liver, excluding animals producing
milk for human consumption. Following examination
those
of
maximum residue limits, it is considered appropriate to

the modification of

an application for

(1) OJ L 224, 18.8.1990, p. 1. Regulation as

(EC) No 1451/2006 (OJ

last amended by
L 271,

Commission Regulation
30.9.2006, p. 37).

Article 2

This Regulation shall enter into force on the third day following
its publication in the Official Journal of the European Union.

It shall apply from 21 January 2007.

(2) OJ L 311, 28.11.2001, p. 1. Directive as last amended by Directive

2004/28/EC (OJ L 136, 30.4.2004, p. 58).

(1)

(2)

(3)

24.11.2006

EN

Official Journal of the European Union

L 325/7

This Regulation shall be binding in its entirety and directly applicable in all Member States.

Done at Brussels, 23 November 2006.

For the Commission

Günter VERHEUGEN
Vice-President

L 325/8

EN

Official Journal of the European Union

24.11.2006

s
e
u
s
s
i
t

t
e
g
r
a
T

s
L
R
M

s
e
i
c
e
p
s

l
a
m
n
A

i

e
u
d
i
s
e
r

r
e
k
r
a
M

)
s
(
e
c
n
a
t
s
b
u
s

e
v
i
t
c
a

l

y
l
l
a
c
i
g
o
o
c
a
m
r
a
h
P

i

s
e
l
o
z
a
d
m
i
z
n
e
b
-
o
r
p

d
n
a

i

s
e
l
o
z
a
d
m
i
z
n
e
B

.

.

3
1
2

.

X
E
N
N
A

:

0
9
/
7
7
3
2

o
N

)

C
E
E
(

n
o
i
t
a
l
u
g
e
R

o
t

I

x
e
n
n
A

n

i

d
e
t
r
e
s
n

i

s
i

e
c
n
a
t
s
b
u
s

i

g
n
w
o

l
l

o
f

e
h
T

.

A

s
e
t
i
s
a
r
a
p
o
d
n
e

t
s
n
i
a
g
a

g
n
i
t
c
a

s
t
n
e
g
A

.

1
2

.

s
t
n
e
g
a

c
i
t
i
s
a
r
a
p
i
t
n
A

.

2

e
l
c
s
u
M

y
e
n
d
K

i

r
e
v
i
L

t
a
F

g
k
/
g

g
k
/
g

g
k
/
g

g
k
/
g

μ

μ

μ

μ

5
2
2

0
0
1

0
5
2

0
5
1

)
1
(

s
t
n
a
n
m
u
r

i

l
l

A

e
b

y
a
m

t
a
h
t

s
e
u
d
i
s
e
r

e
l
b
a
t
c
a
r
t
x
e

f
o

m
u
S

e
l
o
z
a
d
n
e
b
a
l
c
i
r
t
o
t
e
k

o
t

d
e
s
i
d
i
x
o

e
l
o
z
a
d
n
e
b
a
l
c
i
r
T

‘

:

0
9
/
7
7
3
2

o
N

)

C
E
E
(

n
o
i
t
a
l
u
g
e
R

o
t

I
I
I

x
e
n
n
A

n

i

d
e
t
r
e
s
n

i

s
i

e
c
n
a
t
s
b
u
s

i

g
n
w
o

l
l

o
f

e
h
T

.

B

s
t
n
e
g
a

y
r
o
t
a
m
m
a
l
f
n
i
-
i
t
n
a

i

l
a
d
o
r
e
t
s
-
n
o
N

.

1
5

.

s
t
n
e
g
a

y
r
o
t
a
m
m
a
l
f
n
i
-
i
t
n
A

.

5

’

.

n
o
i
t
p
m
u
s
n
o
c

n
a
m
u
h

r
o
f

k

l
i

m

g
n
i
c
u
d
o
r
p

s
l
a
m
n
a

i

n

i

e
s
u

r
o
f

t
o
N

)
1
(

s
e
u
s
s
i
t

t
e
g
r
a
T

s
L
R
M

s
e
i
c
e
p
s

l
a
m
n
A

i

e
u
d
i
s
e
r

r
e
k
r
a
M

)
s
(
e
c
n
a
t
s
b
u
s

e
v
i
t
c
a

l

y
l
l
a
c
i
g
o
o
c
a
m
r
a
h
P

s
e
n
o
t
c
a
l

l
y
n
e
h
p

d
e
t
a
n
o
f
l
u
S

.

.

4
1
5

.

e
l
c
s
u
M

r
e
v
i
L

t
a
F

y
e
n
d
K

i

g
k
/
g

g
k
/
g

g
k
/
g

g
k
/
g

μ

μ

μ

μ

0
1

5
1

0
6

0
1

e
a
d
i
u
q
E

b
i
x
o
c
o
r
i
F

)
1
(

b
i
x
o
c
o
r
i
F

‘

’

.

7
0
0
2

y
l
u
J

1

n
o

e
r
i
p
x
e

s
L
R
M

l
a
n
o
i
s
i
v
o
r
P

)
1
(